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Aims Percutaneous coronary intervention (PCI) in diabetic patients is associated with an increased risk of restenosis and
major adverse cardiac events (MACE). We assessed the impact of diabetes on long-term outcome after PCI with
sirolimus-eluting (SES) and paclitaxel-eluting (PES) stents.
Methods
and results
In the SIRTAX trial, 1012 patients were randomized to treatment with SES (n ¼ 503) or PES (n ¼ 509). A stratified
analysis of outcomes was performed according to the presence or absence of diabetes. Baseline characteristics were
well balanced between SES and PES in patients with (N ¼ 201) and without diabetes (N ¼ 811). Clinical outcome was
worse in diabetic compared with non-diabetic patients regarding death (9.0% vs. 4.1%, P ¼ 0.004) and MACE (defined
as cardiac death, myocardial infarction, or TLR; 19.9% vs. 12.7%, P ¼ 0.007) at 2 years. Among diabetic patients, SES
reduced MACE by 47% (14.8% vs. 25.8%, HR ¼ 0.52, P ¼ 0.05) and TLR by 61% (7.4% vs. 17.2%, HR ¼ 0.39,
P ¼ 0.03) compared with PES at 2 years.
Conclusion Diabetic patients have worse prognosis than non-diabetic patients undergoing PCI with DES. Among the diabetic
patient population of this trial, SES reduce repeat revascularization procedures and MACE more effectively than
PES and to a similar degree as in non-diabetic patients.
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Introduction
Percutaneous coronary intervention (PCI) in diabetic patients is
associated with an increased risk of adverse clinical outcome com-
pared with those without diabetes.1–4 Recently, a meta-analysis of
four trials comparing sirolimus-eluting stents (SES) with bare metal
stents (BMS) suggested an increased risk of mortality with SES,
although event rates were unusually low in the BMS group.5 Dia-
betic patients are also at increased risk of restenosis. Angiographic
and ultrasonic studies suggest a higher degree of late loss (LL)1 and
neointimal hyperplasia6 in diabetic compared with non-diabetic
patients as potential mechanism underlying this phenomenon. In
addition, diabetic patients tend to have smaller vessels,7,8 and
vessel size remains an important predictor of restenosis even in
the era of drug-eluting stents (DES).9,10
SES5,11–13 and paclitaxel-eluting stents (PES)14–19 markedly
reduce angiographic and clinical measures of restenosis compared
with BMS in patients with and without diabetes. However, the rela-
tive efficacy of SES and PES in diabetic patients remains unclear.
Several registries comparing SES and PES in diabetic patients
revealed no differences in outcome regarding restenosis and
repeat revascularization procedures.20–23 A recent systematic
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review of 10 randomized trials indirectly comparing SES with PES
reported superior outcome regarding restenosis and major
adverse cardiac events (MACE) with SES in non-diabetic patients,
whereas there was no difference between both stent types in dia-
betic patients.24 One dedicated randomized trial directly compar-
ing SES and PES in 250 diabetic patients observed significantly
lower LL and restenosis in favour of SES,25 but the study was
not powered to detect differences in clinical outcome.
The objective of the present study was to evaluate the long-
term clinical outcome of patients stratified according to diabetic
status, which was a pre-specified stratified analysis of the random-
ized SIRTAX trial.26
Methods
Patient population and intervention
The design of the SIRTAX trial has been previously reported.26 It was
an observer blind, randomized controlled trial comparing safety and
efficacy of SES and PES in 1012 patients undergoing PCI. Eligible
patients had a history of stable angina or acute coronary syndrome
and presented with at least one lesion with a diameter stenosis
50% in a vessel with a reference vessel diameter (RVD) between
2.25 and 4.00 mm suitable for stent implantation. There were no limit-
ations on the number of treated lesions and vessels, or lesion length.
The study complied with the Declaration of Helsinki regarding investi-
gations in humans and was approved by the institutional ethics com-
mittees at the University Hospitals of Bern and Zurich, Switzerland.
All patients provided written informed consent.
Patients were randomly assigned on a 1 : 1 basis to treatment with
SES (Cypherw; Cordis) or PES (Taxusw, Boston Scientific). Before or
at the time of the procedure, patients received at least 100 mg of
aspirin, a 300 mg loading dose of clopidogrel, and unfractionated
heparin (70–100 U/kg of body weight). After the procedure, all
patients were advised to maintain aspirin lifelong, and clopidogrel
therapy was prescribed for 12 months irrespective of stent type.
Study endpoints and definitions
Adverse events were assessed in hospital, at 1, 6, and 9 months, 1 and
2 years. An independent clinical events committee unaware of the
patients’ treatment assignments adjudicated all endpoints.
The pre-specified primary endpoint was a composite of MACE,
defined as cardiac death, myocardial infarction (MI), or ischaemia-
driven revascularization of the target lesion at 9 months. Secondary
endpoints included ischaemia-driven TLR, TVR, or target-vessel
failure (TVF). TLR and TVR were considered to be driven by ischaemia
if the stenosis of the target lesion or vessel was 50% on the basis of
quantitative coronary angiography in the presence of ischaemic signs
or symptoms, or if there was a stenosis of 70% in the absence of
ischaemic signs or symptoms. TLR was defined as a repeated revascu-
larization based on a stenosis within the stent or within the 5 mm
borders proximal or distal to the stent. The diagnosis of periproce-
dural MI was established whenever new Q-waves of at least 0.4 s
duration in at least two contiguous leads appeared on the electrocar-
diogram with an elevated creatine kinase MB fraction level, or in the
absence of pathological Q waves, an elevation in creatine kinase
levels to more than twice the upper limit of normal with an elevated
creatine kinase MB or troponin I level. Stent thrombosis was defined
as an acute coronary syndrome with angiographic documentation of
either target vessel occlusion or thrombus within or adjacent to the
previously successfully stented segment.
Angiographic core laboratory analysis was performed as previously
described by angiogram readers unaware of the type of stent
implanted.26 Quantitative measurements included RVD, minimal
luminal diameter (MLD), and % diameter stenosis.
Statistical analysis
We pre-specified stratified analysis of the primary outcome accord-
ing to the presence or absence of diabetes. All randomized patients
were included in the analysis of primary and secondary clinical out-
comes in the groups to which they were originally allocated to
(intention-to-treat principle). Baseline characteristics were compared
between diabetic and non-diabetic patients using x2 test without
taking into account the random allocation to SES or PES. We
used a Cox proportional-hazards model to compare clinical out-
comes between the groups. P-values for differences in clinical out-
comes between diabetic and non-diabetic patients were derived
from Cox proportional hazard models adjusted for treatment allo-
cation. To determine whether there was an interaction between
treatment effect and diabetic status, we used likelihood ratio tests.
Analyses were performed in Stata 9.2 (Stata, Inc., College Station,
TX, USA). No adjustments were made for multiple comparisons in
secondary analyses; P-values are two-sided with a significance level
of 0.05.
Results
Baseline clinical, angiographic,
and procedural data
A total of 1012 patients were randomized to treatment with SES
(503 patients with 694 lesions) and PES (509 patients with 715
lesions). Two hundred and one patients (20%) with 292 lesions
were diabetic, of whom 43 patients (21.4%) required insulin.
Among diabetic patients, 108 patients with 158 lesions received
SES, whereas 93 patients with 134 lesions received PES.
Baseline clinical variables were well balanced between SES and
PES in both, diabetic and non-diabetic patients (Table 1). Patients
with diabetes compared with those without diabetes were older
(P, 0.001), more commonly hypertensive (P, 0.001), more
often female (P ¼ 0.01), and had a higher rate of multivessel
disease (P ¼ 0.05). Previous MI (P ¼ 0.06) tended to be more
prevalent, whereas smoking (P, 0.001) was less frequent in dia-
betic than in non-diabetic patients. Target lesion location and
angiographic lesion characteristics at baseline revealed no signifi-
cant differences between SES and PES in diabetic and non-diabetic
patients (Table 2). Procedural and angiographic results are summar-
ized in Table 3, showing similar outcome in SES- and PES-treated
diabetic and non-diabetic patients. Clinical outcomes were
obtained for 1007 (99.5%) of the 1012 randomized patients
during 2 years of follow-up. Five patients lost to follow-up all
belonged to the PES group, three patients were lost during the
first and two patients during the second year.
Clinical outcomes
Clinical events at 2-year follow-up stratified for diabetic status are
summarized in Table 4. Rates of death (9.0% vs. 4.1%, P ¼ 0.004),
cardiac death (7.0% vs. 2.1%, P, 0.001), target lesion
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revascularization (11.9% vs. 10.0%, P ¼ 0.33), and MACE (19.9% vs.
12.7%, P ¼ 0.007) were higher in diabetic than in non-diabetic
patients at 2 years.
Among diabetic patients, SES more effectively reduced MACE
than PES (14.8% vs. 25.8%, HR ¼ 0.52; 95% CI 0.28–0.99;
P ¼ 0.05) (Figure 1A). This difference was largely driven by a
reduction in the risk of TLR in favour of SES (7.4% vs. 17.2%,
HR ¼ 0.39; 95% CI 0.17–0.90; P ¼ 0.03) (Figure 1B). The thera-
peutic benefit of SES over PES in diabetic patients was maintained
at 2 years of follow-up. SES compared with PES reduced rates of
MACE (HR ¼ 0.42, 95% CI 0.19–0.93, P ¼ 0.03) and TLR (HR ¼
0.36, 95% CI 0.13–0.98, P ¼ 0.05) to a similar degree in non-
insulin-dependent diabetics as in non-diabetic patients. In contrast,
rates of MACE were similar for SES (20.0%) and PES (23.5%) in
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Table 2 Baseline lesion characteristics
Diabetic patients Non-diabetic patients P-value
SES PES SES PES
Total number of lesions 158 134 536 581
Target lesion coronary artery [n (%)]
Left main 3 (1.9) 2 (1.5) 8 (1.5) 9 (1.6) 0.82
Left anterior descending 74 (46.8) 62 (46.3) 250 (46.6) 261 (44.9) 0.82
Left circumflex 27 (17.1) 29 (21.6) 112 (20.9) 110 (18.9) 0.80
Right 52 (32.9) 38 (28.4) 157 (29.3) 191 (32.9) 0.93
Bypass graft 2 (1.3) 3 (2.2) 9 (1.7) 10 (1.7) 0.99
ACC-AHA lesion class [n (%)]
A 29 (18.4) 24 (17.9) 102 (19.0) 130 (22.4) 0.37
B1 70 (44.3) 62 (46.3) 230 (42.9) 245 (42.2) 0.46
B2 37 (23.4) 26 (19.4) 137 (25.6) 132 (22.7) 0.43
C 22 (13.9) 22 (16.4) 67 (12.5) 74 (12.7) 0.35
Angiographic measures
Lesion length (mm+ SD) 11.1+5.4 11.8+7.9 12.1+7.4 12.5+7.0 0.10
Reference vessel diameter (mm+ SD) 2.86+0.41 2.74+0.40 2.81+0.40 2.84+0.44 0.51
Minimal lumen diameter (mm+ SD) 0.55+0.49 0.53+0.46 0.52+0.44 0.53+0.42 0.59
Stenosis (% lumen diameter+ SD) 81.4+15.0 80.8+15.6 81.6+15.1 81.3+14.1 0.73
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Table 1 Baseline clinical characteristics
Diabetic patients Non-diabetic patients P-value
SES PES SES PES
Total (n) 108 93 395 416
Age65 years [n (%)] 62 (57.4) 59 (63.4) 155 (39.2) 166 (39.9) ,0.001
Males [n (%)] 75 (69.4) 67 (72.0) 307(77.7) 332 (79.8) 0.01
Hypertension [n (%)] 86 (79.6) 76 (81.7) 216 (54.7) 244 (58.7) ,0.001
Hyperlipidaemia [n (%)] 71 (65.7) 52 (55.9) 234 (59.2) 240 (57.7) 0.48
Current smoking [n (%)] 25 (23.2) 16 (17.2) 159 (40.3) 165 (39.7) ,0.001
Previous myocardial infarction [n (%)] 38 (35.2) 32 (34.4) 107 (27.1) 120 (28.9) 0.06
Stable angina pectoris [n (%)] 60 (55.6) 48 (51.6) 186 (47.1) 198 (47.6) 0.11
Acute coronary syndromes [n (%)] 48 (44.4) 45 (48.4) 209 (52.9) 218 (52.4) 0.21
Unstable angina [n (%)] 6 (5.6) 7 (7.5) 22 (5.6) 23 (5.5)
Non-ST-elevation MI [n (%)] 22 (20.4) 23 (24.7) 90 (22.8) 100 (24.0)
ST-elevation MI [n (%)] 20 (18.5) 15 (16.1) 97 (24.6) 95 (22.8)
Multivessel disease [n (%)] 75 (69.4) 57 (61.3) 225 (57.0) 245 (58.9) 0.05
Left anterior descending coronary artery as target vessel [n (%)] 57 (52.8) 52 (55.9) 211 (53.4) 223 (53.6) 0.86
Small vessel disease [n (%)] 57 (52.8) 50 (53.8) 186 (47.1) 215 (51.7) 0.34
Long target lesion 23 (21.3) 19 (20.4) 78 (19.8) 98 (23.6) 0.77
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Table 3 Procedural results
Diabetic patients Non-diabetic patients P-value
SES PES SES PES
Total number of lesions 158 134 536 581
Procedures
Lesions treated per patient (n+ SD) 1.46+0.65 1.44+0.63 1.36+0.57 1.40+0.59 0.13
Stents per lesion (n+ SD) 1.14+0.45 1.13+0.40 1.11+0.36 1.16+0.46 0.90
Minimal stent diameter (mm+ SD) 2.89+0.40 2.80+0.36 2.88+0.37 2.91+0.37 0.10
Stent length per lesion (mm+ SD) 18.5+10.7 18.7+12.1 18.7+10.2 19.0+10.3 0.71
Maximal pressure (atm+ SD) 14.4+3.2 13.9+2.7 14.4+3.2 14.1+2.9 0.65
Angiographic results
Final minimal lumen diameter (mm+SD)
In-stent 2.66+0.36 2.62+0.41 2.65+0.37 2.69+0.38 0.34
In-segment 2.57+0.40 2.55+0.40 2.55+0.41 2.61+0.44 0.66
Final stenosis (% of lumen diameter+ SD)
In-stent 7.57+4.75 6.82+8.24 7.20+4.75 6.78+4.67 0.58
In-segment 8.92+7.47 8.92+6.61 8.87+7.32 8.26+6.56 0.62
Acute gain (mm+ SD)
In-stent 2.11+0.51 2.09+0.51 2.13+0.52 2.16+0.51 0.23
In-segment 2.10+0.53 1.94+0.57 2.06+0.53 2.10+0.55 0.33
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Table 4 Clinical events through 2 years stratified by diabetes
Diabetic patients Non-diabetic patients P-value for
interaction*
SES PES Hazard ratio
(95% CI)
P-value SES PES Hazard ratio
(95% CI)
P-value
Total number of
patients (n)
108 93 395 416
Events at 24 months
[n (%)]
Death 9 (8.3) 10 (10.8) 0.75 (0.30–1.83) 0.52 16 (4.1) 17 (4.1) 0.98 (0.50–1.95) 0.99 0.62
Cardiac death 7 (6.5) 7 (7.5) 0.83 (0.29–2.37) 0.73 6 (1.5) 11 (2.6) 0.57 (0.21–1.54) 0.27 0.61
Myocardial infarction 2 (1.9) 6 (6.5) 0.28 (0.06–1.38) 0.12 16 (4.1) 18 (4.3) 0.93 (0.48–1.83) 0.84 0.15
Q-wave 0 (0.0) 2 (2.2) 0.17 (0.01–3.56) 0.13 8 (2.0) 5 (1.2) 1.69 (0.55–5.16) 0.36 0.14
Non-Q-wave 2 (1.9) 4 (4.3) 0.43 (0.08–2.33) 0.32 8 (2.0) 13 (3.1) 0.64 (0.27–1.55) 0.33 0.65
Target lesion
revascularization
8 (7.4) 16 (17.2) 0.39 (0.17–0.90) 0.03 31 (7.9) 50 (12.0) 0.64 (0.41–1.00) 0.05 0.32
Percutaneous 6 (5.6) 14 (15.1) 0.33 (0.13–0.86) 0.02 29 (7.3) 44 (10.6) 0.68 (0.42–1.08) 0.10 0.19
Surgical 2 (1.9) 4 (4.3) 0.41 (0.08–2.25) 0.31 3 (0.8) 10 (2.4) 0.31 (0.09–1.13) 0.08 0.80
Target vessel
revascularization
10 (9.3) 17 (18.3) 0.48 (0.22–1.05) 0.07 37 (9.4) 57 (13.7) 0.67 (0.44–1.02) 0.06 0.47
Percutaneous 8 (7.4) 15 (16.1) 0.41 (0.17–0.97) 0.04 35 (8.9) 51 (12.3) 0.70 (0.46–1.08) 0.11 0.28
Surgical 2 (1.9) 4 (4.3) 0.41 (0.08–2.25) 0.31 3 (0.8) 10 (2.4) 0.31 (0.09–1.13) 0.08 0.80
Stent thrombosis 1 (0.9) 3 (3.2) 0.27 (0.03–2.60) 0.26 11 (2.8) 11 (2.6) 1.06 (0.46–2.43) 0.94 0.25
Major adverse cardiac
events
16 (14.8) 24 (25.8) 0.52 (0.28–0.99) 0.05 40 (10.1) 63 (15.1) 0.65 (0.44–0.96) 0.03 0.58
Target vessel failure 18 (16.7) 25 (26.9) 0.57 (0.31–1.04) 0.07 44 (11.1) 70 (16.8) 0.64 (0.44–0.93) 0.03 0.73
Death, myocardial
infarction, or stent
thrombosis
11 (10.2) 16 (17.2) 0.52 (0.22–1.19) 0.12 31 (7.9) 33 (7.9) 1.06 (0.63–1.76) 0.85 0.15
*P-values for interaction relate to differences in hazard ratios between diabetic and non-diabetic patients.
Hazard ratios and P-values are from Cox Proportional Hazards Models.
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insulin-dependent diabetic patients (HR ¼ 0.80, 95% CI 0.28–2.31,
P ¼ 0.68).
There were no significant differences between SES and PES in
diabetics with respect to death (P ¼ 0.52), cardiac death
(P ¼ 0.73), or MI (P ¼ 0.12) at 2 years. Stent thrombosis
amounted to 0.9% for SES and 3.2% for PES (HR ¼ 0.27; 95% CI
0.03–2.60, P ¼ 0.25), and the composite of death, MI, or stent
thrombosis was 10.2% for SES and 17.2% for PES (HR ¼ 0.52,
95% CI 0.22–1.19, P ¼ 0.12) in diabetic patients.
Among patients without diabetes, the rates of MACE (10.4% vs.
15.1%, HR ¼ 0.65, 95% CI 0.44–0.96; P ¼ 0.04) and TLR (7.9% vs.
12.0%, HR ¼ 0.64, 95% CI 0.41–1.00, P ¼ 0.05) were lower for
SES than for PES at 2 years. There were no significant differences
regarding death (P ¼ 0.99), cardiac death (P ¼ 0.27), or MI
(P ¼ 0.84) during long-term follow-up. Similarly, there were no
differences regarding stent thrombosis (SES: 2.8% vs. PES: 2.6%,
HR ¼ 1.06; 95% CI 0.46–2.43, P ¼ 0.94) and the composite of
death, MI, or stent thrombosis (SES: 7.9% vs. PES: 7.9%, HR ¼
1.06, 95% CI 0.63–1.76, P ¼ 0.85) in non-diabetic patients. None
of the tests for interaction between diabetes status and treatment
effect of SES compared with PES reached conventional levels of
statistical significance.
Discussion
The principal findings of the present study can be summarized
as follows.
(i) Diabetic patients have worse prognosis than non-diabetic
patients undergoing PCI with DES.
(ii) SES more effectively reduce the rates of MACE and TLR than
PES in diabetic patients.
(iii) The therapeutic benefit of SES over PES in diabetic patients
was maintained over 2 years of follow-up.
(iv) There were no significant differences between SES and PES in
diabetic patients with respect to death, cardiac death, or MI
over 2 years of follow-up.
SES have been invariably shown to afford lower LL in all trials with
angiographic follow-up directly comparing SES and PES.25–31
Although the impact of small differences of LL on clinical
Figure 1 Kaplan–Meier cumulative event curves of (A) major adverse cardiac events in patients with diabetes stratified for stent type and (B)
target lesion revascularization in patients with diabetes stratified for stent type.
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outcome at the low end of the scale remains a source of debate, it
may be of particular importance in diabetic patients with smaller
vessels.1,6 Since a constant amount of neointimal hyperplasia
results in a proportionally higher grade diameter stenosis in small
as opposed to large vessels, the more potent suppression of neoin-
timal hyperplasia associated with SES compared with PES results in
lower rates of restenosis and TLR in small vessel studies.9,10,30,32
Along this line, three trials with a sizeable diabetic patient popu-
lation (ISAR-DIABETES:25 N ¼ 250; REALITY:29 N ¼ 486;
SIRTAX: N ¼ 201) consistently showed significantly lower LL in
favour of SES (Figure 2A). Binary restenosis was remarkably
similar among diabetic patients in ISAR-DIABETES (SES: 6.9%;
PES 16.5%) and the present study (SES: 7.6%; PES: 17.0%) as was
TLR. Surprisingly and for reasons which are not clear, binary rest-
enosis (SES: 15.9%; PES: 13.2%, P ¼ 0.20; Figure 2B) tended to be
higher in SES- than in PES-treated diabetic patients in REALITY
despite overall lower LL, whereas the relative risk (RR) reduction
of restenosis afforded by SES among non-diabetic patients was
similar in the present study (SES: 6.4% vs. 10.8%, P ¼ 0.07) and
REALITY (7.2% vs. 10.3%, P ¼ 0.06).
Several reports from registries and meta-analyses challenge
the notion that SES are more effective than PES in diabetic patients.
Thus, Ong et al.20 reported no significant difference between SES
(145 patients) and PES (148 patients) in diabetic patients regarding
death (7.7% vs. 7.2%, P ¼ 0.90), and the composite of death and
MI (14.1% vs. 10.0%, P ¼ 0.30) at 1 year. A non-significant trend
in favour of PES was noted with respect to TLR (8.8% vs. 5.7%,
P ¼ 0.08) and MACE (20.4% vs. 15.6%, P ¼ 0.12), which was
maintained at 2-year follow-up.23 Stankovic et al.21 also observed
no difference between SES and PES regarding TLR (18.4% vs.
15.9%, P ¼ 0.61) and MACE (27.2% vs. 22.1%, P ¼ 0.35) in 260
consecutive diabetic patients at 9 months. Similarly, Kuchulakanti
et al.33 reported comparable outcomes of SES and PES
with respect to death (7% vs. 7%, P ¼ 1.0), MI (17% vs. 20%,
P ¼ 0.32), revascularization, and MACE (11% vs. 12%, P ¼ 0.52)
at 6 months follow-up. When comparing the results of these
registries with the present study, the non-randomized nature
and the absence of prospectively defined outcome parameters
of the former need to be considered, potentially leading to con-
founding by indication and performance bias, and spurious find-
ings related to multiple testing.
A systematic review analysed 10 randomized trials with 4513
patients comparing SES (RAVEL, SIRIUS, E-SIRIUS, C-SIRIUS,
SES-SMART, DIABETES) or PES (TAXUS I, II, IV, VI) with BMS.24
Using indirect comparisons in which two interventions were com-
pared through their estimated RR vs. BMS, separate analyses were
performed for the overall population and for patients with and
without diabetes. In patients without diabetes, SES were superior
to PES with respect to in-stent (RR ¼ 0.21, 95% CI 0.10–0.48, P,
0.001), and in-segment restenosis (0.47, 0.24–0.92, P ¼ 0.027),
TLR (0.54, 0.30–0.99, P ¼ 0.045), and MACE (0.46, 0.26–0.83,
P ¼ 0.010). In contrast, there were no significant differences
Figure 2 Bar graph (with 95% confidence intervals) showing (A) late luminal loss for three trial directly comparing sirolimus-eluting (SES) and
paclitaxel-eluting (PES) stents: ISAR-DIABETES, REALITY, SIRTAX and (B) in-segment binary restenosis for three trial directly comparing SES
and PES: ISAR-DIABETES, REALITY, SIRTAX.
Two-year clinical outcome after implantation of SES and PES 723
between the two DES in patients with diabetes for all of the above
endpoints. The mean RVD was smaller for SES (RVD ¼ 2.52 mm)
than for PES (RVD ¼ 2.81 mm) treated vessels, and confounding
by vessel diameter may have diminished the true difference
between the devices in terms of restenosis and repeat revasculariza-
tion. For MACE, there was overlap of confidence intervals of the
treatment effects observed in the systematic review using indirect
comparisons and those of the current study for both, diabetic and
non-diabetic individuals. Regarding TLR, the present study showed
a more pronounced effect of SES compared with PES in diabetic
patients, whereas estimates were again comparable in both studies
for non-diabetic individuals. In view of the fact that the present
study included a considerably smaller number of diabetic patients
than the previous indirect analysis, the lower estimates could be
influenced by chance. On the other hand, it has been shown pre-
viously that adjusted indirect comparisons not always agree with
the results of head to head randomized trials.34
A meta-analysis of four trials suggested an increased risk of mor-
tality with SES compared with BMS in diabetic, but not in non-
diabetic patients.5 Event rates were unusually low in the BMS
group with no difference in mortality between diabetic and non-
diabetic patients. Chance could therefore have contributed to
these results, despite their statistical significance. More recently,
a network meta-analysis of 38 trials in 18 023 patients observed
no difference regarding the risk of death or MI between SES,
PES, and BMS at any time point during long-term follow-up to 4
years.35 A stratified analysis in 3762 diabetic and 10 355 non-
diabetic patients confirmed that the presence or absence of
diabetes did not alter the comparative safety of these stent types
in terms of death or the combined endpoint of death or MI.
Among diabetic patients, the risks of death or the composite of
death or MI were similar in SES, PES, and BMS.
Study limitations
This study is a subgroup analysis of a randomized trial not primarily
dedicated to diabetic patients and was not adequately powered to
detect treatment-subgroup interactions. However, patient and
lesion characteristics were similar between SES- and PES-treated
patients, minimizing the risk of selection bias. Moreover, prospec-
tive follow-up at predefined intervals allowed to extend the obser-
vation period to 2 years of follow-up. Differences regarding
medical treatment with evidence-based medications including
beta-blockers, angiotensin-converting enzyme inhibitors, and
statins may have important effects on long-term clinical
outcome, particularly in high-risk individuals such as diabetic
patients. Owing to incomplete data collection and validation, the
present manuscript does not address potential differences
between the treatment groups regarding medical treatment.
Conclusions
Diabetic patients continue to have worse prognosis than non-
diabetic patients when undergoing PCI with DES. Compared
with PES, SES more effectively reduce repeat revascularization pro-
cedures and MACE in the diabetic patient population of this trial. In
light of the heterogeneous outcome with SES and PES in diabetic
patients emerging from registries, indirect and direct comparisons,
and meta-analyses, a large scale, multi-centre trial comparing the
efficacy of the two DES in diabetic patients is desirable.
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